

KURZPROTOKOLL
Paragon

Öffentlicher Titel	Register für Patienten mit Bauchspeicheldrüsenkrebs
Wissenschaftl. Titel	PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Kurztitel	Paragon
Studienart	multizentrisch, prospektiv, offen/unverblindet, einarmig, Register, nicht-interventionelle Studie, Investigator Initiated Trial (IIT)
Studienphase	nicht zutreffend
Erkrankung	Verdauung: Bauchspeicheldrüsenkrebs (Pankreaskarzinom): weitere
Einschlusskriterien	- Written informed consent and signed data protection form before any study specific intervention, including screening, will be done - Age $\geq$ 18 years - Histologically or cytologically confirmed pancreatic adenocarcinoma - Systemic neoadjuvant, adjuvant, 1st line systemic therapy is planned or recently started (within last 14 days)
Ausschlusskriterien	- Patients who are unable to consent because they do not understand the nature, significance and implications of the study - Patients who are unable to understand or fill out the QoL survey - Patients in 2nd or further treatment lines that have not been documented for 1st line therapy within the study
Alter	18 - 99 Jahre
Prüfzentren	Klinikum Fulda (Rekrutierung beendet) Pacelliallee 4 36043 Fulda Dr. med. Andreas Dickhut Tel: 0661 845487 Fax: 0661 845484 roswitha.rausch@klinikum-fulda.de
Sponsor	IKF GmbH
Förderer	Celgene GmbH
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT04119362
Links	Zu den Ein- und Ausschlusskriterien